Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q56885796 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241121000123.0 | ||
| 008 | 241121nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q56885796 | ||
| 024 | ‡a 0000-0002-0742-1209 ‡2 orcid | ||
| 024 | ‡a 22034584400 ‡2 scopus | ||
| 035 | ‡a (OCoLC)Q56885796 | ||
| 100 | 0 | ‡a Luis León ‡c researcher ‡9 en | |
| 400 | 0 | ‡a Luis León ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Stu | ||
| 670 | ‡a Author's Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis | ||
| 670 | ‡a Author's Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group | ||
| 670 | ‡a Author's Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). | ||
| 670 | ‡a Author's CT perfusion in oncologic imaging: a useful tool? | ||
| 670 | ‡a Author's Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. | ||
| 670 | ‡a Author's Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor | ||
| 670 | ‡a Author's First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients | ||
| 670 | ‡a Author's Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group | ||
| 670 | ‡a Author's Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. | ||
| 670 | ‡a Author's Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients | ||
| 670 | ‡a Author's Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study | ||
| 670 | ‡a Author's Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients | ||
| 670 | ‡a Author's Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel. | ||
| 670 | ‡a Author's Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study | ||
| 670 | ‡a Author's Molecular basis of hypertension side effects induced by sunitinib | ||
| 670 | ‡a Author's New advances in genitourinary cancer: evidence gathered in 2014. | ||
| 670 | ‡a Author's Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. | ||
| 670 | ‡a Author's PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis | ||
| 670 | ‡a Author's Poxviral-based prostate-specific antigen vaccine in prostate cancer. | ||
| 670 | ‡a Author's PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system. | ||
| 670 | ‡a Author's [Quality of life after biochemical recurrence in patients with prostate cancer. How and how long do patients live after biochemical recurrence?] | ||
| 670 | ‡a Author's Quality of life and supportive care for patients with metastatic renal cell carcinoma. | ||
| 670 | ‡a Author's Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. | ||
| 670 | ‡a Author's Radium-223 international early access program: results from the Spanish subset. | ||
| 670 | ‡a Author's Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. | ||
| 670 | ‡a Author's Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer | ||
| 670 | ‡a Author's Sorafenib in renal cell carcinoma | ||
| 670 | ‡a Author's Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases | ||
| 670 | ‡a Author's [The immunohistochemical expression of cyclin B1 is associated with higher SUV in 18F-FDG-PET in non-small cell lung cancer patients. Initial results]. | ||
| 670 | ‡a Author's [The immunohistochemical expression of cyclooxygenase 2 is inversely associated with | ||
| 670 | ‡a Author's The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results | ||
| 670 | ‡a Author's [The maximum standardized uptake value | ||
| 670 | ‡a Author's The maximum standardized uptake value (18)F-FDG PET is independent of the immunohistochemical expression of platelet derived endothelial growth factor in patients with non-small cell lung cancer | ||
| 670 | ‡a Author's Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors. | ||
| 670 | ‡a Author's [Use of M-VAC in the adjuvant treatment of sarcomatoid carcinoma of the bladder] | ||
| 670 | ‡a Author's [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate | ||
| 670 | ‡a Author's [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors] | ||
| 909 | ‡a (scopus) 22034584400 ‡9 1 | ||
| 909 | ‡a (orcid) 0000000207421209 ‡9 1 | ||
| 919 | ‡a gemcitabineplusvinorelbineforthetreatmentofadvancednonsmallcelllungcancer ‡A Gemcitabine plus vinorelbine for the treatment of advanced non-small cell lung cancer. ‡9 1 | ||
| 919 | ‡a gemcitabinecisplatinandvinorelbineasinductionchemotherapyfollowedbyradicaltherapyinstage3nonsmallcelllungcanceramulticentrestudyofgalicianlungcancergroup ‡A Gemcitabine, cisplatin and vinorelbine as induction chemotherapy followed by radical therapy in stage III non-small-cell lung cancer: a multicentre study of galician-lung-cancer-group ‡9 1 | ||
| 919 | ‡a 1linebevacizumabcisplatinandvinorelbineplusmaintenancebevacizumabinadvancednonsquamousnonsmallcelllungcancerchemonaivepatients ‡A First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients ‡9 1 | ||
| 919 | ‡a enzalutamideanewprostatecancertargetedtherapyagainsttheandrogenreceptor ‡A Enzalutamide: a new prostate cancer targeted therapy against the androgen receptor ‡9 1 | ||
| 919 | ‡a developmentofdenovopsoriasisduringnivolumabtherapyformetastaticrenalcellcarcinomaimmunohistochemicalanalysesandclinicaloutcome ‡A Development of de novo psoriasis during nivolumab therapy for metastatic renal cell carcinoma: immunohistochemical analyses and clinical outcome. ‡9 1 | ||
| 919 | ‡a ctperfusioninoncologicimagingausefultool ‡A CT perfusion in oncologic imaging: a useful tool? ‡9 1 | ||
| 919 | ‡a biweeklyadministrationofdocetaxelandvinorelbineas2linechemotherapyforpatientswithstageiiiband4nonsmallcelllungcanceraphase2studyofthegalicianlungcancergroupggcp01302 ‡A Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 013-02). ‡9 1 | ||
| 919 | ‡a biweeklyadministrationofdocetaxelandvinorelbineas2linechemotherapyforpatientswithstageiiiband4nonsmallcelllungcanceraphase2studyofthegalicianlungcancergroup ‡A Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group ‡9 1 | ||
| 919 | ‡a associationofsalivaryhumanpapillomavirusinfectionandoralandoropharyngealcancerametaanalysis ‡A Association of Salivary Human Papillomavirus Infection and Oral and Oropharyngeal Cancer: A Meta-Analysis ‡9 1 | ||
| 919 | ‡a prospectiveobservationalstudyforassessmentandoutcomeassociationofcirculatingendothelialcellsinclearcellrenalcellcarcinomapatientswhoshowinitialbenefitfrom1linetreatmentthecirclescirculatingendothelialcellsstu ‡A A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Stu ‡9 1 | ||
| 919 | ‡a radium223dichlorideanewparadigminthetreatmentofprostatecancer ‡A Radium-223 dichloride: a new paradigm in the treatment of prostate cancer. ‡9 1 | ||
| 919 | ‡a radium223internationalearlyaccessprogramresultsfromthespanishsubset ‡A Radium-223 international early access program: results from the Spanish subset. ‡9 1 | ||
| 919 | ‡a recommendationsfortheclinicalandradiologicalevaluationofresponsetotreatmentinmetastaticrenalcellcancer ‡A Recommendations for the clinical and radiological evaluation of response to treatment in metastatic renal cell cancer. ‡9 1 | ||
| 919 | ‡a recommendationsfromthespanishoncologygenitourinarygroupforthetreatmentofpatientswithmetastaticcastrationresistantprostatecancer ‡A Recommendations from the Spanish Oncology Genitourinary Group for the treatment of patients with metastatic castration-resistant prostate cancer ‡9 1 | ||
| 919 | ‡a sorafenibinrenalcellcarcinoma ‡A Sorafenib in renal cell carcinoma ‡9 1 | ||
| 919 | ‡a temsirolimusinrenalcellcarcinomawithsarcomatoiddifferentiationareportof3cases ‡A Temsirolimus in renal cell carcinoma with sarcomatoid differentiation: a report of three cases ‡9 1 | ||
| 919 | ‡a immunohistochemicalexpressionofcyclinb1isassociatedwithhighersuvin18ffdgpetinnonsmallcelllungcancerpatientsinitialresults ‡A [The immunohistochemical expression of cyclin B1 is associated with higher SUV in 18F-FDG-PET in non-small cell lung cancer patients. Initial results]. ‡9 1 | ||
| 919 | ‡a immunohistochemicalexpressionofcyclooxygenase2isinverselyassociatedwith ‡A [The immunohistochemical expression of cyclooxygenase 2 is inversely associated with ‡9 1 | ||
| 919 | ‡a immunohistochemicalexpressionofcyclooxygenase2isinverselyassociatedwith18ffdgpetsuvvaluesinnonsmallcelllungcancersinitialresults ‡A The immunohistochemical expression of cyclooxygenase 2 is inversely associated with (18)F-FDG-PET SUV values in non-small-cell lung cancers. Initial results ‡9 1 | ||
| 919 | ‡a maximumstandardizeduptakevalue ‡A [The maximum standardized uptake value ‡9 1 | ||
| 919 | ‡a maximumstandardizeduptakevalue18ffdgpetisindependentoftheimmunohistochemicalexpressionofplateletderivedendothelialgrowthfactorinpatientswithnonsmallcelllungcancer ‡A The maximum standardized uptake value (18)F-FDG PET is independent of the immunohistochemical expression of platelet derived endothelial growth factor in patients with non-small cell lung cancer ‡9 1 | ||
| 919 | ‡a treatmentofsunitinibinducedhypertensioninsolidtumorsbynitricoxiddonors ‡A Treatment Of Sunitinib-Induced Hypertension In Solid Tumors By Nitric Oxid Donors. ‡9 1 | ||
| 919 | ‡a useof1000vacintheadjuvanttreatmentofsarcomatoidcarcinomaofthebladder ‡A [Use of M-VAC in the adjuvant treatment of sarcomatoid carcinoma of the bladder] ‡9 1 | ||
| 919 | ‡a utilityoffdgpetforearlyevaluationofefficiencyofimatinibmesylate ‡A [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate ‡9 1 | ||
| 919 | ‡a utilityoffdgpetforearlyevaluationofefficiencyofimatinibmesylateglivecinthetreatmentofgastrointestinalstromaltumors ‡A [Utility of FDG-PET for early evaluation of efficiency of imatinib mesylate (Glivec) in the treatment of gastrointestinal stromal tumors] ‡9 1 | ||
| 919 | ‡a qualityoflifeandsupportivecareforpatientswithmetastaticrenalcellcarcinoma ‡A Quality of life and supportive care for patients with metastatic renal cell carcinoma. ‡9 1 | ||
| 919 | ‡a qualityoflifeafterbiochemicalrecurrenceinpatientswithprostatecancerhowandhowlongdopatientsliveafterbiochemicalrecurrence ‡A [Quality of life after biochemical recurrence in patients with prostate cancer. How and how long do patients live after biochemical recurrence?] ‡9 1 | ||
| 919 | ‡a predictcliquidbiopsyinprecisiononcologyatechnologytransferexperienceinthespanishhealthsystem ‡A PrediCTC, liquid biopsy in precision oncology: a technology transfer experience in the Spanish health system. ‡9 1 | ||
| 919 | ‡a poxviralbasedprostatespecificantigenvaccineinprostatecancer ‡A Poxviral-based prostate-specific antigen vaccine in prostate cancer. ‡9 1 | ||
| 919 | ‡a pd501inhibitorsincombinationwithchemotherapyas1linetreatmentfornonsmallcelllungcancerapairwisemetaanalysis ‡A PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis ‡9 1 | ||
| 919 | ‡a novelpotentialpredictivemarkersofsunitiniboutcomesinlongtermrespondersversusprimaryrefractorypatientswithmetastaticclearcellrenalcellcarcinoma ‡A Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma. ‡9 1 | ||
| 919 | ‡a newadvancesingenitourinarycancerevidencegatheredin ‡A New advances in genitourinary cancer: evidence gathered in 2014. ‡9 1 | ||
| 919 | ‡a molecularbasisofhypertensionsideeffectsinducedbysunitinib ‡A Molecular basis of hypertension side effects induced by sunitinib ‡9 1 | ||
| 919 | ‡a methylphenidateinthemanagementofastheniainbreastcancerpatientstreatedwithdocetaxelresultsofapilotstudy ‡A Methylphenidate in the management of asthenia in breast cancer patients treated with docetaxel: results of a pilot study ‡9 1 | ||
| 919 | ‡a metastaticcastrationresistantprostatecancerchanginglandscapewithcabazitaxel ‡A Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel. ‡9 1 | ||
| 919 | ‡a improvingcirculatingtumorcellsenumerationandcharacterizationtopredictoutcomein1linechemotherapymcrpcpatients ‡A Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients ‡9 1 | ||
| 919 | ‡a impactonclinicalpracticeoftheimplementationofguidelinesforthetoxicitymanagementoftargetedtherapiesinkidneycancertheprotect2study ‡A Impact on clinical practice of the implementation of guidelines for the toxicity management of targeted therapies in kidney cancer. The protect-2 study ‡9 1 | ||
| 919 | ‡a globalgeneexpressioncharacterizationofcirculatingtumorcellsinmetastasiccastrationresistantprostatecancerpatients ‡A Global Gene Expression Characterization of Circulating Tumor Cells in Metastasic Castration-Resistant Prostate Cancer Patients ‡9 1 | ||
| 943 | ‡a 201x ‡A 2014 ‡9 1 | ||
| 996 | ‡2 LC|nr 96019264 | ||
| 996 | ‡2 NTA|074842595 | ||
| 996 | ‡2 BNCHL|10000000000000000796594 | ||
| 996 | ‡2 ISNI|0000000041637420 | ||
| 996 | ‡2 ISNI|0000000039411414 | ||
| 996 | ‡2 LC|no2013086381 | ||
| 996 | ‡2 BNF|12555921 | ||
| 996 | ‡2 BNE|XX1770551 | ||
| 996 | ‡2 LC|n 2005004657 | ||
| 996 | ‡2 SUDOC|083300287 | ||
| 996 | ‡2 BNCHL|10000000000000000280596 | ||
| 996 | ‡2 BIBSYS|90382067 | ||
| 996 | ‡2 LC|n 83016851 | ||
| 996 | ‡2 J9U|987007264412905171 | ||
| 996 | ‡2 ISNI|000000003117387X | ||
| 996 | ‡2 LC|no2012094692 | ||
| 996 | ‡2 ISNI|0000000409022257 | ||
| 996 | ‡2 DNB|140462074 | ||
| 996 | ‡2 BNF|14955493 | ||
| 996 | ‡2 ISNI|0000000115569214 | ||
| 996 | ‡2 RERO|A000054320 | ||
| 996 | ‡2 ISNI|0000000423393070 | ||
| 996 | ‡2 BNF|11912469 | ||
| 996 | ‡2 LC|no2013028298 | ||
| 996 | ‡2 ISNI|0000000054301926 | ||
| 996 | ‡2 DNB|105704427X | ||
| 996 | ‡2 ISNI|0000000023227049 | ||
| 996 | ‡2 LC|n 83164257 | ||
| 996 | ‡2 BLBNB|000188440 | ||
| 996 | ‡2 SUDOC|235239275 | ||
| 996 | ‡2 ISNI|000000004917634X | ||
| 996 | ‡2 NSK|000753984 | ||
| 996 | ‡2 NUKAT|n 2006133091 | ||
| 996 | ‡2 ISNI|0000000116239057 | ||
| 996 | ‡2 LC|n 96024910 | ||
| 996 | ‡2 LC|n 81005089 | ||
| 996 | ‡2 PTBNP|1637935 | ||
| 996 | ‡2 DNB|127518339 | ||
| 996 | ‡2 LC|no2023120402 | ||
| 996 | ‡2 NII|DA05103747 | ||
| 996 | ‡2 RERO|A016395090 | ||
| 996 | ‡2 ISNI|0000000076379476 | ||
| 996 | ‡2 SUDOC|23164115X | ||
| 996 | ‡2 RERO|A010486178 | ||
| 996 | ‡2 LC|no2011072084 | ||
| 996 | ‡2 DNB|116918780 | ||
| 996 | ‡2 LC|nr2002039575 | ||
| 996 | ‡2 LC|n 84216781 | ||
| 996 | ‡2 ISNI|0000000039312432 | ||
| 996 | ‡2 NII|DA12735285 | ||
| 996 | ‡2 ISNI|0000000121192417 | ||
| 996 | ‡2 ISNI|0000000059245310 | ||
| 996 | ‡2 BNF|12554257 | ||
| 996 | ‡2 LC|n 50040140 | ||
| 996 | ‡2 CAOONL|ncf11364460 | ||
| 996 | ‡2 BAV|495_343262 | ||
| 996 | ‡2 ISNI|0000000063054883 | ||
| 996 | ‡2 ISNI|0000000447969273 | ||
| 996 | ‡2 DNB|1056743875 | ||
| 996 | ‡2 NUKAT|n 2021004529 | ||
| 996 | ‡2 BNF|12013211 | ||
| 996 | ‡2 BNCHL|10000000000000000158744 | ||
| 996 | ‡2 LC|no2019169992 | ||
| 996 | ‡2 LC|n 90605555 | ||
| 996 | ‡2 BNCHL|10000000000000000011198 | ||
| 996 | ‡2 PLWABN|9810605332005606 | ||
| 996 | ‡2 DNB|1056306912 | ||
| 996 | ‡2 LC|no2010020230 | ||
| 996 | ‡2 SUDOC|148235573 | ||
| 996 | ‡2 LC|n 80023391 | ||
| 996 | ‡2 SELIBR|221409 | ||
| 996 | ‡2 BNE|XX957762 | ||
| 996 | ‡2 ISNI|0000000040534075 | ||
| 996 | ‡2 LC|ns2024002891 | ||
| 996 | ‡2 DNB|1056175605 | ||
| 996 | ‡2 SUDOC|034850023 | ||
| 996 | ‡2 ISNI|0000000044877075 | ||
| 996 | ‡2 LC|no2005053720 | ||
| 996 | ‡2 DNB|1089801661 | ||
| 996 | ‡2 BNE|XX4675276 | ||
| 996 | ‡2 NLA|000035514887 | ||
| 996 | ‡2 LC|n 2004024715 | ||
| 996 | ‡2 LC|n 88107112 | ||
| 996 | ‡2 LC|n 2010056166 | ||
| 996 | ‡2 SUDOC|080480195 | ||
| 996 | ‡2 LC|n 2002033977 | ||
| 996 | ‡2 LNB|LNC10-000011663 | ||
| 996 | ‡2 LC|n 86862306 | ||
| 996 | ‡2 ISNI|0000000500831776 | ||
| 996 | ‡2 LC|n 82258247 | ||
| 996 | ‡2 ISNI|0000000501456007 | ||
| 996 | ‡2 ISNI|000000002705793X | ||
| 996 | ‡2 BNE|XX1527109 | ||
| 996 | ‡2 ISNI|0000000060880338 | ||
| 996 | ‡2 DNB|1053293488 | ||
| 996 | ‡2 DNB|1242729860 | ||
| 996 | ‡2 SUDOC|116795042 | ||
| 996 | ‡2 BNF|11930018 | ||
| 996 | ‡2 LC|n 87807596 | ||
| 996 | ‡2 BNC|981058614111206706 | ||
| 996 | ‡2 LC|n 88231584 | ||
| 996 | ‡2 LC|ns2012001412 | ||
| 996 | ‡2 ISNI|0000000377610600 | ||
| 996 | ‡2 BNE|XX4605524 | ||
| 996 | ‡2 BNCHL|10000000000000000105666 | ||
| 996 | ‡2 RERO|A024406543 | ||
| 996 | ‡2 DNB|1157529208 | ||
| 996 | ‡2 LC|no 96043801 | ||
| 996 | ‡2 NKC|jcu20211105981 | ||
| 996 | ‡2 PLWABN|9810694847905606 | ||
| 996 | ‡2 LC|n 2006211213 | ||
| 996 | ‡2 NYNYRILM|76639 | ||
| 996 | ‡2 ISNI|000000012136977X | ||
| 996 | ‡2 LC|n 2015022726 | ||
| 996 | ‡2 DNB|1057503444 | ||
| 996 | ‡2 NTA|131891588 | ||
| 996 | ‡2 BNC|981058521701606706 | ||
| 996 | ‡2 DNB|1112507582 | ||
| 996 | ‡2 BNCHL|10000000000000000211110 | ||
| 996 | ‡2 BNCHL|10000000000000000158762 | ||
| 996 | ‡2 ISNI|0000000061572505 | ||
| 996 | ‡2 CAOONL|ncf11192933 | ||
| 996 | ‡2 LC|n 2021252476 | ||
| 996 | ‡2 BNE|XX5669431 | ||
| 996 | ‡2 BNE|XX1627913 | ||
| 996 | ‡2 ISNI|0000000447167465 | ||
| 996 | ‡2 BNF|13325925 | ||
| 996 | ‡2 BNC|981058527612506706 | ||
| 996 | ‡2 SUDOC|117792306 | ||
| 996 | ‡2 DNB|1316103544 | ||
| 996 | ‡2 LC|no2018058748 | ||
| 996 | ‡2 LC|no 94005654 | ||
| 996 | ‡2 J9U|987007264413205171 | ||
| 996 | ‡2 LC|n 2001098643 | ||
| 996 | ‡2 ISNI|0000000116579553 | ||
| 996 | ‡2 LC|no2019071227 | ||
| 996 | ‡2 ISNI|0000000021271716 | ||
| 996 | ‡2 BNF|18175783 | ||
| 996 | ‡2 SUDOC|027208125 | ||
| 996 | ‡2 CAOONL|ncf11945228 | ||
| 996 | ‡2 RERO|A003196005 | ||
| 996 | ‡2 DNB|1240908199 | ||
| 996 | ‡2 CAOONL|ncf11051166 | ||
| 996 | ‡2 DNB|1089209592 | ||
| 996 | ‡2 ISNI|000000005940633X | ||
| 996 | ‡2 ISNI|0000000042577319 | ||
| 996 | ‡2 ISNI|0000000076901367 | ||
| 996 | ‡2 LC|no2010160120 | ||
| 996 | ‡2 LC|ns2023003520 | ||
| 996 | ‡2 BNF|12146864 | ||
| 996 | ‡2 LC|ns2012001391 | ||
| 996 | ‡2 BNCHL|10000000000000000285081 | ||
| 996 | ‡2 N6I|vtls001232065 | ||
| 996 | ‡2 DNB|1325579866 | ||
| 996 | ‡2 LC|no2001061477 | ||
| 996 | ‡2 DNB|173044123 | ||
| 996 | ‡2 ISNI|0000000468440299 | ||
| 996 | ‡2 NLA|000035345604 | ||
| 996 | ‡2 SZ|118727532 | ||
| 996 | ‡2 RERO|A012435848 | ||
| 996 | ‡2 DNB|1057631221 | ||
| 996 | ‡2 NTA|067816029 | ||
| 996 | ‡2 RERO|A006127911 | ||
| 996 | ‡2 ISNI|0000000118252351 | ||
| 996 | ‡2 J9U|987007300961105171 | ||
| 996 | ‡2 NTA|133610799 | ||
| 996 | ‡2 LC|n 87143240 | ||
| 996 | ‡2 LC|no2008068958 | ||
| 996 | ‡2 NUKAT|n 2019214447 | ||
| 996 | ‡2 LC|no2007016100 | ||
| 996 | ‡2 LC|no2011047862 | ||
| 996 | ‡2 BNE|XX1644637 | ||
| 996 | ‡2 DNB|142052949 | ||
| 996 | ‡2 DNB|140622314 | ||
| 996 | ‡2 LC|ns2013002566 | ||
| 996 | ‡2 LC|ns2023000996 | ||
| 996 | ‡2 N6I|vtls000090544 | ||
| 996 | ‡2 BNE|XX1013048 | ||
| 996 | ‡2 ISNI|0000000053322936 | ||
| 996 | ‡2 LC|ns2024000440 | ||
| 996 | ‡2 LC|no2004097511 | ||
| 996 | ‡2 BNCHL|10000000000000000075689 | ||
| 996 | ‡2 SUDOC|269879641 | ||
| 996 | ‡2 LC|n 2017010661 | ||
| 996 | ‡2 BNCHL|10000000000000000062387 | ||
| 996 | ‡2 ISNI|0000000033844550 | ||
| 996 | ‡2 DNB|1056375833 | ||
| 996 | ‡2 BNF|13776096 | ||
| 996 | ‡2 DNB|118727532 | ||
| 996 | ‡2 DNB|129870587 | ||
| 996 | ‡2 CAOONL|ncf11698975 | ||
| 996 | ‡2 LC|no2014054685 | ||
| 996 | ‡2 LC|no2017011007 | ||
| 996 | ‡2 ISNI|0000000078221656 | ||
| 996 | ‡2 J9U|987007461547005171 | ||
| 996 | ‡2 DNB|1032470801 | ||
| 996 | ‡2 SUDOC|242249957 | ||
| 996 | ‡2 BNCHL|10000000000000000862008 | ||
| 996 | ‡2 SUDOC|027207080 | ||
| 996 | ‡2 BNCHL|10000000000000000110928 | ||
| 996 | ‡2 NTA|074277227 | ||
| 996 | ‡2 DNB|105737718X | ||
| 996 | ‡2 BNE|XX1719599 | ||
| 996 | ‡2 RERO|A000104521 | ||
| 996 | ‡2 SUDOC|231914806 | ||
| 996 | ‡2 ISNI|0000000049209666 | ||
| 996 | ‡2 BNF|17756118 | ||
| 996 | ‡2 LC|n 80086740 | ||
| 996 | ‡2 DNB|1272802485 | ||
| 996 | ‡2 DNB|1057344966 | ||
| 996 | ‡2 ISNI|0000000122447901 | ||
| 996 | ‡2 LIH|LNB:B_l__o_K;=B4 | ||
| 996 | ‡2 NTA|192708619 | ||
| 996 | ‡2 BNF|10319482 | ||
| 996 | ‡2 ICCU|RAVV050140 | ||
| 996 | ‡2 LC|n 79065135 | ||
| 996 | ‡2 LC|no 99044188 | ||
| 996 | ‡2 LC|no2013061024 | ||
| 996 | ‡2 NYNYRILM|73100 | ||
| 996 | ‡2 NUKAT|n 2004032785 | ||
| 996 | ‡2 LC|n 95075675 | ||
| 996 | ‡2 BNCHL|10000000000000000158759 | ||
| 996 | ‡2 NII|DA10295319 | ||
| 996 | ‡2 LC|n 80086377 | ||
| 996 | ‡2 ISNI|0000000022085376 | ||
| 996 | ‡2 BNE|XX5536269 | ||
| 996 | ‡2 J9U|987007327924005171 | ||
| 996 | ‡2 CAOONL|ncf10328660 | ||
| 996 | ‡2 SUDOC|028259548 | ||
| 996 | ‡2 LC|no2012147122 | ||
| 996 | ‡2 ICCU|CFIV094958 | ||
| 996 | ‡2 BIBSYS|4023376 | ||
| 996 | ‡2 ISNI|0000000115629811 | ||
| 996 | ‡2 LC|n 88117361 | ||
| 996 | ‡2 PLWABN|9810660869805606 | ||
| 996 | ‡2 RERO|A003540594 | ||
| 996 | ‡2 BNF|16588965 | ||
| 996 | ‡2 SUDOC|120121212 | ||
| 996 | ‡2 BNCHL|10000000000000000121836 | ||
| 996 | ‡2 ARBABN|000028018 | ||
| 996 | ‡2 LC|n 97089059 | ||
| 996 | ‡2 SUDOC|029952581 | ||
| 996 | ‡2 BNF|10725655 | ||
| 996 | ‡2 PTBNP|34088 | ||
| 996 | ‡2 BNC|981058521393506706 | ||
| 996 | ‡2 BNE|XX828867 | ||
| 996 | ‡2 RERO|A022608923 | ||
| 996 | ‡2 SUDOC|134425790 | ||
| 996 | ‡2 LC|n 2005009070 | ||
| 996 | ‡2 SUDOC|18431576X | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
